Development of vericiguat: The first soluble guanylate cyclase (sGC) stimulator launched for heart failure with reduced ejection fraction (HFrEF)-Reference-Cited by-同舟云学术

Development of vericiguat: The first soluble guanylate cyclase (sGC) stimulator launched for heart failure with reduced ejection fraction (HFrEF)

Published:2022-05 Issue: Volume:149 Page:112894
ISSN:0753-3322
Container-title:Biomedicine & Pharmacotherapy
language:en
Short-container-title:Biomedicine & Pharmacotherapy

Author:

Xia Juan,Hui Nan,Tian Lei,Liang Chengyuan,Zhang Jie,Liu Jifang,Wang Jun,Ren Xiaodong,Xie Xiaolin,Wang Kun

Publisher

Elsevier BV

Subject

Pharmacology,General Medicine

Reference121 articles.

1. Molecular and cellular mechanisms in heart failure;Puggia,2018

2. Heart failure with reduced ejection fraction: a review;Murphy;JAMA,2020

3. National Clinical Guideline, National Institute for Health and Clinical Excellence: Guidance, Chronic Heart Failure: National Clinical Guideline for Diagnosis and Management in Primary and Secondary Care: Partial Update, Royal College of Physicians (UK)Copyright © 2010, National Clinical Guideline Centre, London, 2010.

4. Epidemiology of heart failure;Groenewegen;Eur. J. Heart Fail.,2020

5. The year in cardiovascular medicine 2020: heart failure and cardiomyopathies;Bueno;Eur. Heart J.,2021

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inhibition of P-Glycoprotein Asymmetrically Alters the In Vivo Exposure Profile of SGC003F: A Novel Guanylate Cyclase Stimulator;Pharmaceuticals;2024-08-29

2. A Review of Contemporary and Future Pharmacotherapy for Chronic Heart Failure in Children;Children;2024-07-16

3. Vericiguat in patients with heart failure across the spectrum of left ventricular ejection fraction: a patient-level, pooled meta-analysis of VITALITY-HFpEF and VICTORIA;Frontiers in Endocrinology;2024-03-08

4. Renal and cardiac effects of the PDE9 inhibitor BAY 73–6691 in 5/6 nephrectomized rats;Pflügers Archiv - European Journal of Physiology;2024-02-02

5. Vericiguat and transcatheter edge-to-edge mitral valve repair for combined post- and pre-capillary pulmonary hypertension due to left ventricular low ejection fraction and functional mitral regurgitation;Journal of Cardiology Cases;2024-02